Severe asthma and eligibility for biologics in a Brazilian cohort

References

• GINA. Global Initiave for Asthma. Global Strategy for Asthma Management and Prevention 2018. [accessed Sept 2019]. www.ginasthma.org.
   Google Scholar
• Pearce N, Ait-Khaled N, Beasley R, Mallol J, Keil U, Mitchell E, Robertson C, and the ISAAC Phase Three Study Group. Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC. Thorax. 2007;62(9):758–766. doi:10.1136/thx.2006.070169.
   PubMed Web of Science ®Google Scholar
• Sunyer J, Anto JM, Tobias A, Burney P. Generational increase of self-reported first attack of asthma in fifteen industrialized countries. European Community Respiratory Health Study (ECRHS). Eur Respir J. 1999;14:885–891. doi:10.1034/j.1399-3003.1999.14d26.x.
   PubMed Web of Science ®Google Scholar
• Deliu M, Yavuz TS, Sperrin M, Belgrave D, Sahiner UM, Sackesen C, Kalayci O, Custovic A. Features of asthma which provide meaningful insights for understanding the disease heterogeneity. Clin Exp Allergy. 2018;48(1):39–47. doi:10.1111/cea.13014.
   PubMed Web of Science ®Google Scholar
• Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, D'Agostino R, Castro M, Curran-Everett D, Fitzpatrick AM, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010;181(4):315–323. doi:10.1164/rccm.200906-0896OC.
   PubMed Web of Science ®Google Scholar
• Hekking PP, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896–902. doi:10.1016/j.jaci.2014.08.042.
   PubMed Web of Science ®Google Scholar
• Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Resp J. 2014;43(2):343–373. doi:10.1183/09031936.00202013.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Mantzouranis E, Cruz AA, Ait-Khaled N, Baena-Cagnani CE, Bleecker ER, Brightling CE, Burney P, Bush A, Busse WW, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol. 2010;126(5):926–938. doi:10.1016/j.jaci.2010.07.019.
   PubMed Web of Science ®Google Scholar
• Chung KF, Godard P, Adelroth E, Ayres J, Barnes N, Barnes P, Bel E, Burney P, Chanez P, Connett G, et al. Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. Eur Respir J. 1999;13:1198–1208. doi:10.1034/j.1399-3003.1999.13e43.x.
   PubMed Web of Science ®Google Scholar
• Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, Chanez P, Enright PL, Gibson PG, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180(1):59–99. doi:10.1164/rccm.200801-060ST.
   PubMed Web of Science ®Google Scholar
• Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. Am J Respir Crit Care Med. 2000;162:2341–2351. doi:10.1164/ajrccm.162.6.ats9-00.
   PubMedGoogle Scholar
• Godar M, Blanchetot C, de Haard H, Lambrecht BN, Brusselle G. Personalized medicine with biologics for severe type 2 asthma: current status and future prospects. MAbs. 2018;10(1):34–45. doi:10.1080/19420862.2017.1392425.
   PubMed Web of Science ®Google Scholar
• Viswanathan RK, Busse WW. Biologic therapy and asthma. Semin Respir Crit Care Med. 2018;39(01):100–114. doi:10.1055/s-0037-1606218.
   PubMed Web of Science ®Google Scholar
• Pepper AN, Renz H, Casale TB, Garn H. Biologic therapy and novel molecular targets of severe asthma. J Allergy Clin Immunol Pract. 2017;5(4):909–916. doi:10.1016/j.jaip.2017.04.038.
   PubMed Web of Science ®Google Scholar
• Lougheed MD. Choosing wisely in the era of biologics for asthma. Ann Allergy Asthma Immunol. 2018;120(4):345–346. doi:10.1016/j.anai.2017.11.013.
   PubMed Web of Science ®Google Scholar
• Ponte E, Franco RA, Souza-Machado A, Souza-Machado C, Cruz ÁA. Impacto de um programa para o controle da asma grave na utilização de recursos do Sistema Único de Saúde. J Bras Pneumol. 2007;33(1):15–19. doi:10.1590/S1806-37132007000100006.
   PubMedGoogle Scholar
• Ponte EV, Almeida PCA, Biao-Lima V, Figueiredo CA, Riley JH, Myles D, Bansal AT, Souza-Machado A, Group PS. Cross-sectional analysis of adults with previously untreated severe asthma (SA) followed up aftertreatment: A Brazilian severe asthma cohort (ProAR). Am J Respir Crit Care Med. 2018;197:A1382. doi:10.1164/ajrccm-conference.2018.197.1_MeetingAbstracts.A1382.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health NH, Lung, and Blood Institute. Practical guide for the diagnosis and management of asthma. National Asthma Education Prevention Program. 1997. [last accessed Sept 2019]. https://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln_archive.pdf.
   Google Scholar
• Lima-Matos A, Ponte EV, de Jesus JPV, Almeida PCA, Lima VB, Kwon N, Riley J, de Mello LM, Cruz ÁA. Eosinophilic asthma, according to a blood eosinophil criterion, is associated with disease severity and lack of control among underprivileged urban Brazilians. Respir Med. 2018;145:95–100. doi:. doi:10.1016/j.rmed.2018.10.025.
   PubMed Web of Science ®Google Scholar
• Juniper EF, Svensson K, Mork AC, Stahl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med. 2005;99(5):553–558. doi:10.1016/j.rmed.2004.10.008.
   PubMed Web of Science ®Google Scholar
• Koshak EA. Classification of asthma according to revised 2006 GINA: evolution from severity to control. Ann Thorac Med. 2007;2(2):45–46. doi:10.4103/1817-1737.32228.
   PubMedGoogle Scholar
• Shaw DE, Sousa AR, Fowler SJ, Fleming LJ, Roberts G, Corfield J, Pandis I, Bansal AT, Bel EH, Auffray C, et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J. 2015;46(5):1308–1321. doi:10.1183/13993003.50779-2015.
   PubMed Web of Science ®Google Scholar
• Heffler E, Blasi F, Latorre M, Menzella F, Paggiaro P, Pelaia G, Senna G, Canonica GW, Barbuto S, Bradicich M, et al. The Severe Asthma Network in Italy: Findings and Perspectives. J Allergy Clin Immunol Pract. 2018;7(5):1462–1468. doi:https://doi.org/ doi:10.1016/j.jaip.2018.10.016.
   PubMed Web of Science ®Google Scholar
• Kim MH, Kim SH, Park SY, Ban GY, Kim JH, Jung JW, Moon JY, Song WJ, Kwon HS, Kwon JW, et al. Characteristics of adult severe refractory asthma in korea analyzed from the severe asthma registry. Allergy Asthma Immunol Res. 2019;11(1):43–54. doi:10.4168/aair.2019.11.1.43.
   PubMed Web of Science ®Google Scholar
• Alves AM, Marques de Mello L, Lima Matos AS, Cruz AA. Severe asthma: Comparison of different classifications of severity and control. Respir Med. 2019;156:1–7. doi:10.1016/j.rmed.2019.07.015.
   PubMed Web of Science ®Google Scholar
• Albers FC, Mullerova H, Gunsoy NB, Shin JY, Nelsen LM, Bradford ES, Cockle SM, Suruki RY. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study. J Asthma. 2018;55(2):152–160. doi:10.1080/02770903.2017.1322611.
   PubMed Web of Science ®Google Scholar
• Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ, British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum. 2007;56(1):13–20. doi:10.1002/art.22331.
   PubMed Web of Science ®Google Scholar
• Chipps BE, Haselkorn T, Paknis B, Ortiz B, Bleecker ER, Kianifard F, Foreman AJ, Szefler SJ, Zeiger RS. More than a decade follow-up in patients with severe or difficult-to-treat asthma: The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) II. J Allergy Clin Immunol. 2018;141(5):1590–1597. e1599. doi:10.1016/j.jaci.2017.07.014.
   PubMed Web of Science ®Google Scholar
• Jang AS. Steroid response in refractory asthmatics. Korean J Intern Med. 2012;27(2):143–148. doi:10.3904/kjim.2012.27.2.143.
   PubMed Web of Science ®Google Scholar
• Athanazio R, Carvalho-Pinto R, Fernandes FL, Rached S, Rabe K, Cukier A, Stelmach R. Can severe asthmatic patients achieve asthma control? A systematic approach in patients with difficult to control asthma followed in a specialized clinic. BMC Pulm Med. 2016;16(1):153. doi:10.1186/s12890-016-0314-1.
   PubMed Web of Science ®Google Scholar
• Tay TR, Hew M. Comorbid “treatable traits” in difficult asthma: Current evidence and clinical evaluation. Allergy. 2018;73(7):1369–82. doi:10.1111/all.13370.
   PubMed Web of Science ®Google Scholar
• Chung KF. Diagnosis and Management of Severe Asthma. Semin Respir Crit Care Med. 2018;39(1):91–99. doi:10.1055/s-0037-1607391.
   PubMed Web of Science ®Google Scholar
• Marques de Mello L, Cruz ÁA. A proposed scheme to cope with comorbidities in asthma. Pulm Pharmacol Ther. 2018;52:41–51. doi:. doi:10.1016/j.pupt.2018.08.005.
   PubMed Web of Science ®Google Scholar
• Hekking PP, Amelink M, Wener RR, Bouvy ML, Bel EH. Comorbidities in difficult-to-control asthma. J Allergy Clin Immunol Pract. 2018;6(1):108–113. doi:10.1016/j.jaip.2017.06.008.
   PubMed Web of Science ®Google Scholar
• Mäkelä MJ, Backer V, Hedegaard M, Larsson K. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med. 2013;107(10):1481–1490. doi:10.1016/j.rmed.2013.04.005.
   PubMed Web of Science ®Google Scholar
• Björnsdóttir US, Gizurarson S, Sabale U. Potential negative consequences of non-consented switch of inhaled medications and devices in asthma patients. Int J Clin Pract. 2013;67(9):904–910. doi:10.1111/ijcp.12202.
   PubMed Web of Science ®Google Scholar
• Colice GL. Categorizing asthma severity: an overview of national guidelines; 2004. [last accessed Sept 2019]. https://www.ncbi.nlm.nih.gov/pubmed/15931352.
   Google Scholar
• Lommatzsch M, Virchow JC. Severe asthma: definition, diagnosis and treatment. Dtsch Arztebl Int. 2014;111:847–855. doi:10.3238/arztebl.2014.0847.
   PubMed Web of Science ®Google Scholar